@Article{
AUTHOR = {Konaté-Touré, Abibatou Konaté-Touré and Dablé, Marius T. Dablé and Bédia-Tanoh, Valérie A. Bédia-Tanoh and Gnagne, Paterne A. Gnagne and Kassi, Fulgence K. Kassi and Koné, Estelle MG Koné and Vanga-Bosson, Henriette Vanga-Bosson and Angora, Etienne K. Angora and Miezan, Jean Sebastien A. Miezan and Djohan, Vincent Djohan and Kiki-Barro, Christiane P. Kiki-Barro and Touré, Offianan A. Touré and Menan, Hervé EI Menan and Yavo, William Yavo},
TITLE = {Temporal Dynamic of Efficacy and Tolerability of Artemether–Lumefantrine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Bouna, Côte d’Ivoire},
JOURNAL = {African Journal of Parasitology, Mycology and Entomology},
VOLUME = {3},
YEAR = {2026},
NUMBER = {2},
PAGES = {0--0},
URL = {https://ajpme.jams.pub/article/3/2/294},
ISSN = {1987-1473},
ABSTRACT = {Introduction: Therapeutic Efficacy Studies (TESs) are crucial for detecting early changes in P. falciparum susceptibility to antimalarial drugs. Artemether–lumefantrine is one of five first-line treatments for uncomplicated malaria in Côte d’Ivoire. This study aimed to assess the temporal dynamics of artemether–lumefantrine (AL) efficacy in managing uncomplicated malaria cases in Bouna, a sentinel site. Methods: This was a comparative analysis of two controlled, randomized, and open therapeutic trials based on a 28-day follow-up period, conducted according to the 2009 WHO protocol. The surveys were conducted in 2019 and 2023. Treatment response was measured and defined following WHO guidelines, with analyses performed using intention-to-treat and per-protocol methods. Results: A 28-day follow-up was performed for 57 and 87 patients in 2019 and 2023, respectively. On day 28, the PCR-adjusted cure rates were higher in 2023 than in 2019, both in ITT analysis (96.6% versus 90.0%) and in PP analysis (97.7% versus 94.7%). However, more failures were observed after 28 days of follow-up in 2023 (23 cases) than in 2019 (9 cases). After PCR adjustment, nearly all cases were attributed to reinfection. In 2019, three cases of recurrence and six new infections were observed. In 2023, two recurrence events and 21 new infections were observed. In both surveys, AL was well-tolerated. Conclusions: This comparative assessment demonstrated that AL remains effective in treating uncomplicated malaria in Bouna. The high number of new infections highlights the need to strengthen preventive measures.},
DOI = {10.35995/ajpme03020011}
}